Trastuzumab Deruxtecan Prolongs OS in Second-Line Treatment for Patients with HER2-positive Metastatic Gastric or GEJ Adenocarcinoma By Ogkologos - July 2, 2025 290 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the DESTINY-Gastric04 study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Poherdy Whole-Genome Sequencing Meets Diagnostic Requirements in Routine Practice for Patients with Solid Cancers FDA Approves Relacorilant with nab-Paclitaxel for Platinum-Resistant Epithelial Ovarian, Fallopian Tube, Or Primary Peritoneal Cancer MOST POPULAR EMA Recommends Granting a Conditional Marketing Authorisation for Mosunetuzumab May 17, 2022 Olivia Newton-John Talks About Her Use Of Medical Cannabis During Cancer... May 28, 2019 27-Year-Old Fighting Stage IV Cancer Gets Hit By COVID-19 And Sepsis... May 29, 2020 Researchers Find a Way to Prevent Cancer Cells from Taking in... July 14, 2020 Load more HOT NEWS For HPV-Positive Women, Test Can Guide Cervical Cancer Screening Follow-Up Analyzing Tumor RNA May Help Match Patients with Most Effective Cancer... ESMO Sarcoma and Rare Cancers Congress 2025, Lugano, Switzerland, 20-22 March Data Shows Women Are Not Getting Access To An Important Part...
